DNTH Stock Forecast: $75 Target by Mid-2026
DNTH stock soars 300% YTD on biotech breakthroughs. Latest DNTH stock price, analyst targets to $81, earnings preview. Is DNTH stock a buy? Introduction Dianthus Therapeutics develops treatments for autoimmune diseases. Its lead drug DNTH103 targets myasthenia gravis and other disorders using precision antibodies.Investors watch DNTH stock after Phase 2 trial success doubled shares in … Read more